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Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a leukodystrophy characterized by
myelin vacuolization and caused by mutations in MLC1 or GLIALCAM. Patients with recessive mutations in
eitherMLC1 or GLIALCAM show the same clinical phenotype. It has been shown that GLIALCAM is necessary
for the correct targeting of MLC1 to the membrane at cell junctions, but its own localization was independent
of MLC1 in vitro. However, recent studies in Mlc12/2 mice have shown that GlialCAM is mislocalized in glial
cells. In order to investigate whether the relationship between Mlc1 and GlialCAM is species-specific, we first
identified MLC-related genes in zebrafish and generated an mlc12/2 zebrafish. We have characterized
mlc12/2 zebrafish both functionally and histologically and compared the phenotype with that of theMlc12/2
mice. Inmlc12/2 zebrafish, as in Mlc12/2 mice, Glialcam is mislocalized. Re-examination of a brain biopsy
from an MLC patient indicates that GLIALCAM is also mislocalized in Bergmann glia in the cerebellum.
In vitro, impaired localization of GlialCAM was observed in astrocyte cultures fromMlc12/2 mouse only in the
presence of elevated potassium levels, which mimics neuronal activity. In summary, here we demonstrate an
evolutionary conserved role for MLC1 in regulating glial surface levels of GLIALCAM, and this interrelationship
explains why patients with mutations in either gene (MLC1 orGLIALCAM) share the same clinical phenotype.
INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts
(MLC) is a rare type of congenital leukodystrophy characterized
mainly by myelin vacuolization and early onset of macrocephaly
(1). Magnetic resonance imaging (MRI) of patient’s brains
shows diffuse signal abnormality, and this method is used for
diagnosis during childhood (2). MLC is caused by mutations
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in eitherMLC1 (MIM #605908) orGLIALCAM (MIM #611642)
genes (3,4).
MLC1 encodes for a membrane protein, which is expressed in
several brain barriers, mainly in ependymal cells, astrocytes sur-
rounding blood vessels and Bergmann radial glia in the cerebel-
lum. In all cells, MLC1 is localized at cell junctions (5–7).
Surprisingly, MLC1 is not expressed in oligodendrocytes, the
site of the primary pathology of MLC (8). Mutations have
been found across the whole coding sequence (3,9–11), which
cause protein folding defects that lead to degradation of MLC1
(12,13). The function of MLC1 is still unknown, although it
has been related to the activation of volume-regulated anion cur-
rents (VRAC) (14,15), involved in cellular osmotic response. It
has been indicated that a reduced VRAC activity may lead to
intracellular water accumulation and to the vacuolization
observed in patients (15,16). In addition, other studies have sug-
gested that MLC1 cooperates with the Na+/K+-ATPase and the
TRPV4 channel (17,18), although the exact mechanism is still
unknown.
GlialCAM (also called HEPACAM due to its original discov-
ery in hepatic cancer cells) is a cell adhesion molecule of the im-
munoglobulin family (19) that is mostly expressed in glial cells
(20) and co-localizes with MLC1 at astrocyte–astrocyte junc-
tions (4). MLC patients with recessive mutations inGLIALCAM
(known as MLC2A type of MLC, MIM #613925) present the
same phenotype as patients carrying recessive mutations in
MLC1 (MLC1 type of MLC, MIM #604004) (4,21). Some
MLC patients have dominant mutations in the GLIALCAM
gene (MLC2B type of MLC, MIM #613926), and these are asso-
ciated to various degrees of phenotypic expression, ranging from
a transient benign form of MLC, to macrocephaly and mental
retardation with or without autism (4,21).
Both data obtained from in vitro and fromGlialCAM2/2mice
have demonstrated that GlialCAM is necessary for MLC1 to exit
the endoplasmatic reticulum and target cell junctions (13,15,22).
Furthermore, a mistargeting of both GlialCAM and MLC1 to cell
junctions has been shown by in vitro studies with most missense
GLIALCAM mutations (either recessive or dominant) and with
GlialCAMdn/dn knock-in mice harbouring a dominant mutation
(4,13,22,23). In contrast, GlialCAM seems to be able to traffic
to cell junctions by itself (13,19). Thus, the overlapping pheno-
type of MLC1 and MLC2A patients can be understood because
of the cardinal role of MLC1 in the pathogenesis of MLC.
However, GlialCAM, but not MLC1, is detected in oligoden-
drocytes (4,20); it was also found that GlialCAM functions as an
auxiliary glial-specific subunit of the broadly expressed ClC-2
chloride channel (24). Furthermore, MLC-related GLIALCAM
mutations impair the trafficking of ClC-2 to cell junctions
(23,24). Analyses of GlialCAM2/2 and GlialCAMdn/dn knock-in
mice have shown that localization of ClC-2 in glial junctions is
dependent on GlialCAM (22). Thus, based on these in vitro and
in vivo data, patients carrying recessive GLIALCAM mutations
should be more severely affected than patients carrying recessive
MLC1 mutations, as ClC-2 channel may also be affected in those
carrying GLIALCAM mutations. However, there are no clinical
differences between these two types of patients.
Recent studies with Mlc12/2 mice have shown that, contrary
to what was expected based on the lack of direct interaction
between MLC1 and ClC-2, GlialCAM and ClC-2 are misloca-
lized in astrocytes and oligodendrocytes when MLC1 is absent
(22). Based on cell culture data, it was indicated that MLC1
and ClC-2 could indirectly interact through homotypic extracel-
lular GlialCAM-mediated interactions (22), as previously sug-
gested (25). These results indicate that lack of function of
ClC-2 may be involved in the pathogenesis of MLC (22). Lack
of ClC-2 function has also been associated with a distinct form
of leukoencephalopathy (26).
The mislocalization of GlialCAM found in Mlc12/2 mice
contradicts previous results obtained using RNA interference
ofMlc1 in rat astrocytes and localization studies of GLIALCAM
around blood vessels in a sample from an MLC1 patient (13). Al-
though RNA interference may not completely reproduce the
gene knockout phenotype, we have previously shown that
Mlc1 RNAi induces a significant decrease in Mlc1 protein
levels (12,13). Thus, it is unclear if GlialCAM is unstable
without MLC1 only in mice, or whether this is a general
mechanism.
To solve this controversy, we decided to examine the relation-
ship between Mlc1 and GlialCAM in other animal species. We
generated a zebrafish model for MLC based on the lack of
mlc1. As in mice, characterization of the zebrafish model
revealed that loss of mlc1 impairs the correct localization of
glialcam. Re-examination of the brain biopsy from a MLC1
patient that had been previously studied revealed that GlialCAM
was mislocalized in Bergmann glia. These results confirm that
the MLC1-dependent localization of GlialCAM is a general
mechanism, as data from Mlc12/2 mouse had shown. As in
the RNA interference experiments, cultured astrocytes from
Mlc12/2mice show normal GlialCAM localization, but slightly
reduced VRAC activity. However, we observed that mimicking
neuronal activity in Mlc12/2 astrocyte cultures causes Glial-
CAM mislocalization. Hence, data presented here explain previ-
ous discrepancies and reveal a conserved activity-regulated role
of MLC1 in determining the localization of GLIALCAM.
RESULTS
GlialCAM is also mislocalized in Mlc12/2 astrocytes close
to ependymal cells
In situ hybridization and immunohistochemistry studies have
demonstrated that MLC1 and GLIALCAM co-localize in astro-
cytes close to brain barriers, Bergmann glia and ependymal cells,
and that GLIALCAM is additionally expressed in oligodendro-
cytes (4,6,7,20). InMlc12/2 mice, GlialCAM is mislocalized in
astrocytes, Bergmann glia and oligodendrocytes (22). We exam-
ined whether GlialCAM was also mislocalized in ependymal
cells by means of electron microscopy. To our surprise, gold
particle-labelled antibodies showed that Mlc1 is not present in
ependymal cells, but rather in astrocyte–astrocyte contacts
below ependymal cells (Fig. 1A and C). Control experiments
in Mlc12/2 mice confirmed the specificity of the signal
(Fig. 1B and D). GlialCAM co-localized with Mlc1 in subepen-
dymal astrocyte–astrocyte contacts (Fig. 1E and G), and, as
observed previously in astrocytes and oligodendrocytes, Glial-
CAM was also mislocalized in astrocytes near ependymal cells
in Mlc12/2 mice (Fig. 1F and H). Thus, we conclude that the
absence of Mlc1 in mice causes mistargeting of GlialCAM in
all types of glial cells.
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Identification of MLC-related genes in zebrafish
To address whether this Mlc1-dependent mislocalization of
GlialCAM was a conserved feature, we decided to generate an
Mlc1-deficient animal model in another species. By means of
sequence database inspection, we found that genes encoding
the orthologue of human MLC1 are present in all vertebrates,
including zebrafish (Danio rerio), that has a single orthologue
(Supplementary Material, Fig. S1A). In contrast, metazoan
model organisms, such as Drosophila melanogaster and
Caenorhabditis elegans, which lack myelin, do not possess
MLC1 orthologues (3). For GLIALCAM, we observed that the
teleost-specific genome duplication yielded two glialcam para-
logues: glialcama and glialcamb (Supplementary Material,
Fig. S2A).
Sequence comparison between zebrafish mlc1 and its human
ortholog showed an overall 53% identity that was higher
(63%) at the putative transmembrane domains and the terminal
part of the C-terminus (Supplementary Material, Fig. S1B).
Both glialcam paralogues showed a 76% identity with human
Figure 1. GlialCAM does not localize to astrocyte junctions in subependymal astrocytes in Mlc12/2 mice. (A–D) EM immunolabelling of ependymal cells shows
localization of Mlc1 in astrocyte–astrocyte junctions (arrows) near ependymal cells (A and C). Dotted lines highlight boundaries between ependymal cells (ec) and
inner astrocytic processes (a). The signal was specific as it was absent in Mlc12/2 mice (B and D). The insets in (A) and (B) are shown amplified in (C) and (D). Scale
bars: (A, B): 2 mm; (C, D): 500 nm. (E–H) EM immunolabelling images of GlialCAM in astrocyte junctions below ependymal cells (arrows) (E, G). GlialCAM
protein could not be observed in astrocyte–astrocyte junctions in Mlc12/2 mice (F, H). The insets in (E) and (F) are shown amplified in (G) and (H). Scale bars:
(E and F): 2 mm; (G and H): 500 nm.
Human Molecular Genetics, 2014, Vol. 23, No. 19 5071
GLIALCAM across the two extracellular Ig-domains and the
putative transmembrane domain, but the conservation of the
C-terminal intracellular domain was very low, saved for a
stretch of residues in the central part (Supplementary Material,
Fig. S2B).
We cloned zebrafishmlc1 and bothglialcamparalogues, fused
to an intracellular FLAG tag, and expressed them transiently in
HeLa cells. Importantly, glialcama could be predominantly
detected in cell junctions (Fig. 2A), while glialcamb was found
in a diffuse manner (Fig. 2B). Like its human counterpart (13),
glialcama was able to target zebrafish mlc1 (Fig. 2C–E) and
rat chloride channel ClC-2 (24) (Fig. 2F–H) to cell junctions.
Furthermore, glialcama and not glialcamb was able to modify
the functional properties of rat ClC-2-mediated currents in
Xenopus oocytes. Glialcama, as with the human ortholog (24),
not only increased ClC-2-mediated currents, but also changed
rectification and activation properties (Fig. 2I–L). To addition-
ally verify that glialcama behaves as human GLIALCAM, we
analysed glialcama variants containing MLC-related mutations
in conserved residues (Supplementary Material, Fig. S2B) that
have previously shown trafficking defects (13). As happened
in human GLIALCAM (4), we observed that the introduction of
MLC-related mutations in glialcama negatively affected its
junctional localization without substantially interfering with
its expression levels (Supplementary Material, Fig. S3A–C).
These results suggest that zebrafish glialcama, and not glial-
camb, could perform the same physiological functions as
human GLIALCAM. Therefore, we decided to focus our
studies on this zebrafish paralogue.
Generation of a mutant mlc1 zebrafish line
We generated a zebrafish mlc1 knockout line by sequencing the
first exons of the mlc1 gene on the ENU-based TILLING library
at the laboratory of Dr C. Moens at the FHCRC (Seattle, USA).
Unfortunately, we did not detect any stop, frameshift or splice
site mutations that would potentially abolish normal protein
expression. However, we detected a missense mutation
(c.241T.G) in one allele (mlc1fh328), resulting in the substitu-
tion of a conserved hydrophobic residue (isoleucine) for a
charged one (arginine; p.81I.R) on the predicted first trans-
membrane domain of the protein. We hypothesized that the
introduction of a positive charge in the transmembrane domain
could be deleterious for its protein expression. In order to test
this, we introduced the equivalent mutation (V64R, Supplemen-
tary Material, Fig. S1B) in human MLC1 carrying HA epitope
tags (one at the N-terminus and the other extracellular) and
assayed surface expression by an ELISA-based luminescence
assay in Xenopus oocytes (Fig. 3A). We used oocytes because
their incubation temperature (188C) would reveal whether the
mutation causes folding defects (27). No surface expression
could be detected, confirming our hypothesis that the mutation
was deleterious.
Therefore, the heterozygous founder zebrafish were pair-wise
mated and out-crossed for several generations to eliminate any
other background mutations from the original ENU mutagenesis
(see Materials and Methods). As the mutation results in a novel
DdeI restriction site, it was possible to perform RFLP genotyp-
ing, and gene sequencing confirmed the presence of the mutation
(Fig. 3B and C). As our previous antibodies against human or
mouse Mlc1 proteins did not recognize the zebrafish orthologue
(data not shown), we developed a new rabbit polyclonal antibody
that was able to detect zebrafish mlc1 (Fig. 3D and E). We
assayed mlc1 expression in brain extracts from wild-type,
heterozygous and homozygous mlc1fh328 adult fish siblings.
No mlc1 protein expression could be detected in homozygotes,
validating the allele mlc1fh328 as an mlc1 knockout line, which
we will refer to as mlc12/2 zebrafish from now on (Fig. 3F).
As with the Mlc12/2 mouse (22), the homozygous mlc12/2
zebrafish turned out to be viable and fertile, with the expected
mendelian ratio among adult descendants.
Expression pattern of mlc1 in the adult zebrafish brain
and retina
We determined the expression pattern ofmlc1 in adult tissues by
RT-qPCR (Fig. 4A) and western blot (Fig. 4B). This showed that
mlc1 is mainly expressed in the brain and at reduced levels in the
eye. We performed immunofluorescence experiments to deter-
mine which cell types express mlc1 in the adult brain, using
themlc12/2 zebrafish as a control. Prominent immunoreactivity
was observed at the ventricular and pial surface of the brain, and
around some blood vessels (Fig. 4C, D, F). Additionally, mlc1
immunoreactivity was observed in radial processes within the
brain parenchyma (Fig. 4D). Lack of staining in the mlc12/2
zebrafish brain confirmed the specificity of our results
(Fig. 4E). Staining of mlc1 in the transgenic line fli1a:GFP,
which expresses GFP in the vascular endothelium (28), con-
firmed that the mlc1 protein is present at astrocytic perivascular
processes (Fig. 4F). mlc1 staining around brain ventricles and
radial-like structures was also positive for glial fibrillary acid
protein (gfap) antibody (Fig. 4G and H), indicating that these
are astroglial-like cells (29). Thus, expression of mlc1 in the
zebrafish brain is very similar to that found in humans.
We also analysed the localization of mlc1 in the retina. High
expression of mlc1 was detected at the inner limiting membrane
of the retina. Specificity of the antibody was confirmed by lack of
staining in mlc12/2 zebrafish retina (Fig. 4I and J). Double
immunostaining with gfap demonstrated that mlc1 was strongly
expressed in Mu¨ller glia end-feet in the inner limiting membrane
(Fig. 4K). Furthermore, we also observed weak mlc1 and gfap
co-expression at fine radial glial processes away from the
vitreal surface of the retina (Fig. 4K).
Glialcama localization in the adult brain and retina
is affected in mlc12/2 zebrafish
As with mlc1, we determined the pattern of expression of glial-
cama using RT-qPCR in adult tissues. mRNA for glialcamawas
more broadly expressed compared with mlc1, but showed the
highest expression levels in the brain. Detection of glialcama
protein in tissue extracts by western blot using a newly devel-
oped glialcama antibody (Supplementary Material, Fig. S3D)
confirmed its higher expression in the brain (Fig. 5B), and its
presence in the eye.
We next addressed the localization of glialcama in brain and
retina from wild-type and mlc12/2 zebrafish (Fig. 5C and D).
Similar to mlc1, we detected strong immunoreactivity to glial-
cama in radial glial cell bodies and their processes (Fig. 5C
and D), which were also positive for gfap (Fig. 5E). In contrast,
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Figure 2. Characterization of the zebrafish orthologues of Mlc1 and Glialcam. (A and B) glialcama and glialcamb were transfected separately in HeLa cells and
detected through the FLAG epitope with immunofluorescence. While glialcama is specifically located in cell–cell junctions, glialcamb protein presented a
diffuse location. Scale bar: 10 mm. (C–E) Co-transfection of glialcama and mlc1 in HeLa cells reveals their co-localization at cell junctions. Scale bar: 10 mm.
(F–H) Co-transfection ofglialcamaand ratClC-2 in HeLa cells reveals their co-localization at cell junctions.Scale bar: 10 mm. (I–L) A typical current trace mediated
by rat ClC2 (I) expressed in oocytes and after co-expression with glialcama (J) or glialcamb (K). Only glialcama is able to modify the functional properties of ClC-2.
The apparent inactivation observed sometimes at very negative voltages is an artefact caused by chloride depletion inside the oocytes (J). (L) Average steady-state
current–voltage relationship of ClC-2 (black circles) and ClC-2 co-expressed with glialcama (white circles) or with glialcamb (triangles). Glialcama increased
ClC-2-mediated conductance and changed its rectification properties.
Human Molecular Genetics, 2014, Vol. 23, No. 19 5073
a more diffuse glialcama staining was observed in the same brain
regions in mlc12/2 zebrafish (Fig. 5F). We addressed if lack of
detection was due to reduced protein expression by western blot
using brain extracts, but no changes in protein expression levels
were observed (Fig. 5G). We also studied glialcama localization
in the retina, as its laminar arrangement could allow easier visu-
alization of subcellular mislocalization. As observed for mlc1,
glialcama was highly expressed at Mu¨ller glia end-feet at the
inner limiting membrane (Fig. 5H and I). This expression was
absent in mlc12/2 zebrafish. Thus, as we observed in the
brain, glialcama was mislocalized in the retina of mlc12/2
zebrafish (Fig. 5J).
We can conclude that lack of mlc1 in zebrafish causes glial-
cama mislocalization in glial cells in the brain and retina, in a
similar manner to that found in Mlc12/2 mice (22).
Comparison of mouse and zebrafish Mlc1 knockout
phenotypes
The phenotypes of Mlc1 mouse and zebrafish knockouts were
compared. Histopathology of brain sections from Mlc12/2
mice revealed largely restricted myelin vacuolization in fibre
tracts of the cerebellum (22). In agreement with these histology
results, T2-weighted MRI of the brain of Mlc1
2/2 mice showed
lesions in white matter tracts of the cerebellum from about
6 months of age that increased with age (Fig. 6A and B).
Measurement of brain volume revealed that the whole brain is
bigger in Mlc12/2 than in wild-type mice at the same age
(Fig. 6G).
In zebrafish, we analysed the brain of four adult (14 months
old) mlc12/2 zebrafish by MRI. We only observed very minor
lesions in the telencephalon and mesencephalon (Fig. 6C–F)
which showed similar relaxation times as cerebrospinal fluid,
thus suggesting that they were due to increased fluid. As in
mice, measurements of different brain areas revealed that the
telencephalon seems larger in comparison with the whole
brain in mutant than in wild-type zebrafish (Fig. 6H).
Thus, both animal models showed two typical MLC features:
megalencephaly and increased fluid accumulation. However, we
failed to observe the presence of vacuoles in any region of
the zebrafish brain by general histological procedures (eight
different animals; Supplementary Material, Fig. S4A and B) or
electron transmission microscopy (four different animals;
Supplementary Material, Fig. S4E and F). We conclude that
the mlc12/2 zebrafish develops less severe lesions than the
Mlc12/2 mice in the brain, which in turn also develops a less
severe phenotype than humans.
As glialcama and mlc1 are co-expressed in Mu¨ller cells in the
retina, we also studied and compared retina morphology
between mice and zebrafish. As in Mlc12/2 mice (22), the
retina ofmlc12/2 zebrafish did not show lesions after histologic-
al staining (Supplementary Material, Fig. S4C and D). We also
Figure3.Generation of a zebrafish model for MLC based on the inactivation of mlc1. (A) Expression inXenopusoocytes of human MLC1 carrying the V64R mutation
abolishes its surface expression, as assayed by detection by an ELISA-based assay. (B) Restriction analysis withDdeI allows for the identification of wild-type (+/+),
heterozygous (+/2) or homozygous mutant (2/2) fish of the mlc1fh328 allele. m: molecular weight marker. (C) Zebrafish mlc1fh328 allele originates the I81R mu-
tation, and generates a DdeI restriction site. (D and E) Custom-generated antibody against mlc1 detects a protein of the expected molecular weight (around 42 kDa,
arrowhead) and its localization in the membraneonmlc1-transfected HeLa cells. The band observedat about 85 kDa corresponds to mlc1dimers. Scale bar (E): 10 mm.
(F) Western blot of brain extracts from adult wild-type (+/+), heterozygous (+/2) or homozygous mutant (2/2) fish for the mlc1fh328 allele demonstrates the
absence of the mlc1 protein in the homozygous zebrafish.
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evaluated the visual function by recording electro-retinograms
(ERG) inMlc12/2mice andmlc12/2 zebrafish (Supplementary
Material, Fig. S5). No significant differences of the means of
b-wave amplitude between wild-type and mlc12/2 fish at any
light condition were observed (Supplementary Material,
Fig. S5A). The relation of normalized b-wave amplitude and
the light intensity (inset in Supplementary Material, Fig. S5A)
showed complete overlaps between the two groups, suggesting
that the sensitivity in mlc12/2 fish does not differ from wild-
types. Similar observations have been found in 2-month-old
adults (Supplementary Material, Fig. S5B). Similar tests were
performed on 1-year-old adult Mlc12/2 mice. Analysis of the
Figure 4.mlc1 expression and localization pattern in adult zebrafish. (A) qPCR with RNA from adult tissues shows the expression of mlc1 almost exclusively in the
brain, and at a lesser level in the eye. (B) Western blot with the custom mlc1 antibody shows its expression on the brain and eye. As controls, we used extracts from
mlc1-transfected and untransfected HeLa cells. (C–F) Immunofluorescence detection of mlc1 in the zebrafish adult brain. (C) mlc1 is expressed in radial glia pro-
cesses (arrow) and pial end-feet (arrowheads). (D) mlc1 expression surrounds the ventricle of the brain (open arrow). (E) No immunoreactivity is observed inmlc12/2.
Arrowheads point to the pial surface of the brain. Scale bars: 20 mm. (F) Localization of mlc1 (red) in glial perivascular processes (arrowheads) around blood vessels
(green) in the brain of afli1a::GFP transgeniczebrafish. Scale bar: 10 mm. (GandH) mlc1co-localizes with the astrocytic proteingfap in the zebrafishadult brainat the
pial (arrowhead in G) and ventricular surfaces of the brain (open arrow in H). Asterisk labels the ventricle. Scale bars: 15 mm. Inset: gfap and mlc1 co-expression at
the cell body and radial processes of an astrocyte located in a subependymal zone. Scale bar: 15 mm. (I–K) Localization of mlc1 on the retina. (I) mlc1 is expressed in
the inner limiting membrane (arrows) of the retina. (J) No immunoreactivity against mlc1 is observed in mlc12/2 zebrafish retina. (K) Double immunofluorescence
with gfap (red) confirms mlc1 expression (green) in radial glia processes and Mu¨ller glia end-feet (arrow) at inner limiting membrane. Scale bars: 100 mm.
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amplitudes of the different components of the ERG showed no
significant differences between wild-type and Mlc12/2 mice
(Supplementary Material, Fig. S5C).
Human GLIALCAM is also mislocalized in the Bergmann
glia of a MLC1 patient
Our studies with Mlc12/2 mice and mlc12/2 zebrafish have
revealed mislocalization of GlialCAM in astrocytes and oligo-
dendrocytes. However, previous studies from a biopsy of a
MLC patient indicated that GLIALCAM was not mislocalized
around blood vessels in the cortex (13).
We re-examined the localization of GLIALCAM in the
cerebellum of this same human brain biopsy. We focused on
the cerebellum, as it is more severely affected in Mlc12/2
mice (22). As previously shown (13), we could not detect
MLC1 in Bergmann glia from the MLC patient (Fig. 7A–F).
In addition, staining with GLIALCAM antibodies revealed
that it was in fact mislocalized in Bergmann glia in the MLC
patient (Fig. 7G–L). Control staining with GFAP revealed that
these changes were not due to defects in the integrity of the
tissue. Thus, we can conclude that the mislocalization of
GLIALCAM caused by the absence of MLC1 is a conserved
feature from fish to humans, even though the phenotype is
more severe as we climb the evolutionary ladder.
VRAC activity in cultured astrocytes fromMlc12/2 mice
is still present
We cultured astrocytes from Mlc12/2 mice and analysed Glial-
CAM localization. Unexpectedly, lack of Mlc1 did not change
GlialCAM localization (Fig. 8A–D) and expression (Fig. 8E)
in Mlc12/2 astrocyte cultures. This result agreed with previous
experiments that showed that knocking down Mlc1 in rat astro-
cytes changed neither the expression nor the localization of
GlialCAM in cell junctions (13).
As MLC1 have been related with the activity of VRAC
(14,15), we analysed chloride currents in Mlc12/2 astrocyte cul-
tures. In wild-type and Mlc12/2 astrocytes, replacing intra- and
extracellular Na+ and K+ ions with Cs+ (to block sodium and po-
tassium currents) and with symmetric Cl2, the whole-cell back-
ground conductance was very low (Fig. 8F). In both type of
astrocytes, hypotonicity challenge promoted a large, reversible
increase in ramp current in the whole range of membrane poten-
tials (Fig. 8F and Supplementary Material, Fig. S6A and C).
These hypotonicity-activated currents reversed at 0 mV,
were blocked by the specific VRAC inhibitor 4-(2-butyl-
6,7-dichlor-2-cyclopentylindan-1-on-5-yl) oxobutyric acid
(DCPIB) (30), and showed instantaneous activation and time-
dependent inactivation at more positive potentials (Fig. 8F and
Supplementary Material, Fig. S6A–D). These data indicated
that hypotonicity-activated VRAC channels in wild-type and
Mlc12/2 mouse astrocytes which are functionally identical to
those described in rat astrocytes (31,32). The observation that
the putative ClC-2 inhibitor cadmium (33) did not affect the
hypotonicity-activated currents (Supplementary Material,
Fig. S6E and F) strongly indicated that these Cl2 currents were
not mediated by ClC-2, which is also present in mouse astrocytes
(34). Comparison of VRAC amplitudes between wild-type and
Mlc12/2 astrocytes indicated that VRAC was slightly reduced
in astrocytes obtained from Mlc12/2 mouse (Fig. 8G). These
results support the view that Mlc1 does not mediate directly
Figure 5.Glialcama is mislocalized in mlc12/2 zebrafish. (A) qPCR with RNA from adult tissues shows the highest expression of glialcama in the brain, but also in
other tissues. (B) Western blot with the custom antibody shows glialcama expression on the brain and eye. (C andD) Immunofluorescence detection of glialcama in the
zebrafish adult brain. We observed glialcam expression both in radial processes (arrowheads in C and D) and end-feet (arrow in D). Scale bars: 50 mm in (C), 20 mm in
(D). (E) Co-localization of glialcama (green) and the astrocytic protein gfap (red) at radial glia processes (arrowheads) and end-feet (arrow). Scale bar: 20 mm.
(F) glialcama signal is more diffuse in the brain of mlc12/2 zebrafish. Scale bar: 50 mm. (G) Expression levels of glialcama in the brain are not different between
wild-type (+/+), heterozygous (+/2) and mlc12/2 zebrafish. Actin level was used as a loading control. (H–J) Localization of glialcama on the retina.
(H) Strong expression is observed at the inner limiting membrane (arrows) of the retina in wild-type zebrafish. (I) Double immunofluorescence with gfap confirms
glialcama expression in Mu¨ller glia end-feet (arrows). Note the funnel-like form of Mu¨ller glia end-feet. (J) Inmlc12/2 zebrafish, only a diffuse labelling is observed
with no strong expression in the inner limiting membrane (asterisk). Scale bars: 100 mm in (H), 20 mm in (I) and (J).
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Figure 6.MRI ofMlc12/2mice andmlc12/2 zebrafish. (A andB) MRI of mice from different ages show progressive presence of white matter lesions (arrows) in the
cerebellum of Mlc12/2 animals (B), but not in wild-type mice (A). (C–F) MRI of adult zebrafish reveals the presence of small lesions in the mesencephalon (thick
arrow in D) and telencephalon (arrows in F) inmlc12/2 zebrafish. Hyperintense signals in (D) and (F) may correspond to fat containing tissue in or around the brain.
(C) and (E) correspond to images from wild-type zebrafish. Scale bars: 1 mm in (C) and (D), 500 mm in (E) and (F). (G) Brain volume is higher inMlc12/2mice. Brain
volume was estimated by quantifying the area of consecutive MRI images using ImageJ. Data correspond to seven wild-type and sevenMlc12/2 mice (P , 0.0001).
(H) Telencephalon appears bigger relative to the whole brain in mlc12/2 zebrafish (P, 0.05).
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VRAC current. To detect whether the non-statistically signifi-
cant VRAC reduction may lead to astrocyte vacuolation, we
stained wild-type (Fig. 8H) and Mlc12/2 astrocytes (Fig. 8I)
with the freely diffusible fluorescent reagent calcein. Vacuoles
were more frequently observed in Mlc12/2 astrocytes (Fig. 8J).
Glialcam localization is dependent on Mlc1 with high
extracellular potassium concentration
Why is GlialCAM mislocalized in Mlc12/2 astrocytes in tissue
and not in culture? Mislocalization of GlialCAM in humans was
better observed in Bergmann glia, which are bathed in a high
extracellular potassium concentration due to cerebellar neuronal
activity (35). Thus, we treated cultured astrocytes obtained from
wild-type andMlc12/2mice with physiological medium or with
an isosmotic solution with higher potassium concentration,
mimicking neuronal activity. In wild-type astrocytes under
high potassium concentration, there was no change on the local-
ization of Mlc1 (Fig. 9A–D), but there was a slight increase of
GlialCAM in cell junctions. When similar experiments were
repeated in astrocytes from Mlc12/2, GlialCAM was detected
intracellularly after high-potassium treatment (Fig. 9E–H).
This effect was even more evident when astrocytes were infected
with adenoviruses expressing human Flag-tagged GLIALCAM
(Fig. 9I–L). Control staining with the junctional marker
b-catenin revealed that these distribution changes caused by
increasing extracellular potassium were specific to GlialCAM
(Fig. 9M–P).
Figure 7.GLIALCAM is mislocalized in the cerebellum of a patient with a missense mutation inMLC1. (A–F) Immunofluorescence detection of MLC1 and GFAP
proteins in the cerebellum of a control subject (A–C) and an MLC patient (D-F) carrying a homozygous mutation inMLC1 shows the absence of the MLC1 protein in
the patient. Scale bar: 40 mm. (G–L) Immunofluorescence detection of GLIALCAM and GFAP proteins in the cerebellum of a control subject (G–I) and an MLC
patient (J–L) carrying a homozygous mutation in MLC1 shows the diffuse signal for GLIALCAM in the absence of MLC1.
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Figure8.CulturedMlc12/2 astrocytes do not show mislocalization of Glialcam and still present a VRAC response. (A andB) Immunofluorescence detection of Mlc1
in cultured astrocytes from newborn pups confirms the absence of the Mlc1 protein inMlc12/2mice. (C andD) Immunofluorescence detection of Glialcam in cultured
astrocytes from newborn pups shows that Glialcam protein is present in cell junctions inMlc12/2mice, unlike it is seen in vivo. Scale bar: 10 mm. (E) Western blot of
brain extracts show no difference in Glialcam protein levels between wild-type andMlc12/2mice. (F andG) Depression of the hypotonicity-evoked chloride current
with the Volume Regulated Anion Channel (VRAC) inhibitor DCPIB in wild-type (WT) andMlc12/2mouse cultured astrocytes. (F) Bar graph of membrane current
densities (mean+SEM) at+80 mV (upper bars) and2120 mV (lower bars) measured in isotonic (Iso CsCl) and hypotonic conditions (Hypo CsCl) and after addition
of DCPIB (10 mM) to the hypotonic solution (Hypo CsCl + DCPIB) in wild-type (n ¼ 9) and Mlc12/2 (n ¼ 17) astrocytes. Statistical significance was calculated
using paired two-tailed Student’s t-test; ∗P , 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001. (G) Bar graph of DCPIB-sensitive currents (mean+SEM) induced by hypotonic chal-
lenge at2120 and+80 mV in wild-type (n ¼ 7) andMlc12/2 (n ¼ 7) mouse astrocytes. Differences in current densities were not significant (ns). (H and I) Typical
pictures of astrocytes obtained from wild-type (H) andMlc12/2 (I) mice. Arrowheads point to vacuoles observed mostly inMlc12/2 astrocytes. (J) Quantification of
the number of cells containing vacuoles. A cell was positive for vacuolation if have at least three vacuoles of a size bigger than 0.5 mm. Scale bar: 10 mm.
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DISCUSSION
We have analysed two animal models (zebrafish, mice) lacking
MLC1 protein and compared them with a brain biopsy from an
MLC patient. In all cases, localization of GlialCAM at cell junc-
tions is abolished by lack of MLC1. In cultured mouse astrocytes
from Mlc12/2, this effect is only observed when mimicking
neuronal activity.
Despite the fact thatMlc1 is one of the most astrocyte-specific
genes (36,37) and its mutation leads to MLC (3), its precise func-
tion is still unknown. As MLC1 is a membrane protein with low
homology to ion channels, a possible role as a channel or trans-
porter has been suggested (6). However, no such function has
been found so far. RNA interference experiments ofMlc1 in cul-
tured astrocytes indicated that it may be a component or regulator
of VRAC (14,15). Here, we demonstrate that VRAC activity is
Figure 9.Glialcam localization to astrocyte junctions depends on Mlc1 and the presence of high extracellular potassium concentration. (A–D) Mlc1 localization in cell
junctions in cultured mouse astrocytes do not change between physiological conditions or high extracellular potassium exposure. Scale bar: 10 mm. (E–H) Glialcam
localization in cell junctions in cultured mouse astrocytes is lost when Mlc12/2 astrocytes are subjected to 6 h treatment with high extracellular potassium. Four inde-
pendent experiments gave similar results. (I–L) Adenoviral-mediated expression of human Flag-tagged GLIALCAM in wild-type andMlc12/2 cultured mouse astro-
cytes confirms the effect of the high extracellular potassium concentration on GlialCAM localization in cell junctions (arrows) in the absence of Mlc1, when it is found
almost exclusively in the cytoplasm (asterisks). Dotted line in (L) labels the junctions between three adjacent astrocytes. Four independent experiments gave similar
results. (M–P) High extracellular potassium concentration does not alter of the localization of a control junctional protein (b-catenin) in cultured mouse astrocytes.
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still present in the absence of Mlc1. We conclude that MLC1 may
affect VRAC activity in an indirect manner and is not a molecu-
lar component of VRAC. In agreement with this hypothesis, very
recently it has been demonstrated that VRAC activity is
mediated by LRRC8 heteromers (38,39). Further work will be
needed to define the biochemical relationship between MLC1/
GlialCAM and LRRC8 proteins.
Further insight into MLC1 biology came from the finding that
another MLC-causing gene, which encodes the cell adhesion
molecule GLIALCAM (4), is necessary for stabilizing and tar-
geting MLC1 to astrocyte junctions (4,15). In contrast, GLIAL
CAM targeting in vitro was independent of MLC1 (19,13).
However, recent work performed with Mlc12/2 and
GlialCAM2/2 mice demonstrated that both mutants reproduce
MLC symptoms and that Mlc1 is necessary for GlialCAM
localization (22).
We decided to expand the repertoire of MLC animal models to
solve this contradiction. We have characterized the orthologues
of MLC1 and GLIALCAM in zebrafish. The zebrafish (and other
teleost fishes) genome contains two glialcam paralogues of
which only glialcama behaves as mammalian Glialcam in
terms of subcellular localization and modulation of the chloride
channel ClC-2 (24). Both mlc1 and glialcama show a similar ex-
pression pattern in the brain as murine Mlc1 and Glialcam (4).
mlc1 and glialcama are localized to glial cells especially
around brain barriers, radial glia processes and end-feet, and
also in Mu¨ller glia of the retina.
We have generated a zebrafish line carrying a mutation inmlc1
that abrogates its protein expression. However, the conservation
of mlc1 in zebrafish does not translate into a severe MLC-like
phenotype. We could only detect minor lesions and megalence-
phaly in the brain of mlc12/2 zebrafish by MRI, but not myelin
vacuolization even in fish older than 1 year. Although in humans
MLC is evident during the first year of life (1), mouse knockout
models of bothGlialcam andMlc1 did not present vacuolization
during their firsts months of life (22). This difference could
reflect their heterochrony of myelination, and that MLC mani-
fests when myelination is at its highest level (1). Zebrafish
show regular compact myelin (40), but protein composition
differs: P0 is the major component of CNS myelin, rather than
PLP, like in mammals (41). In the transition from an aquatic to
a terrestrial environment, there was a switch from P0 to PLP as
the major CNS myelin protein, which provided more neuropro-
tection (42). Myelination in zebrafish larvae starts at 3 days post-
fertilization (dpf), andmyelin basic protein expression increases
at least till 29 dpf (43), but new myelin deposition has been
reported in trout even older than 1 year (44). Another significant
difference with mammalian brains is the capacity of the adult
zebrafish brain for neurogenesis (45) and even repair after
injury (46). This is linked to the capacity for re-myelination
(47,48). Therefore, it is possible to speculate that zebrafish are
able to repair myelin sheath damage produced by the lack of
mlc1 protein, so vacuolization never reaches a detectable stage
by means of histological methods.
Absence of mlc1 in zebrafish brain leads to the misslocaliza-
tion of glialcama, as we observed in Mlc12/2 mice. This
prompted us to re-examine a human MLC biopsy. We found
similar results in the cerebellum of the MLC patient. Thus, the
reciprocal relationship between MLC1 and GlialCAM for their
correct membrane localization has been conserved throughout
evolution. This relationship also explains the fact that mutations
in either MLC1 or GLIALCAM cause a similar phenotype in
MLC1 and MLC2A patients (21).
It has been well described that MLC1 depends on GLIAL
CAM for exiting the endoplasmatic reticulum and reaching its
junctional localization (15). However, a question remains:
why does GLIALCAM mislocalize in the absence of MLC1
in vivo? We believe that MLC1 is not working as a chaperone
of GLIALCAM, as GLIALCAM in vitro is able to traffic to
cell junctions in the absence of MLC1. In agreement with this
hypothesis, GlialCAM mislocalization in Mlc12/2 astrocytes
in culture only appeared when mimicking neuronal activity by
an increase in extracellular potassium. Thus, differences
between in vivo and in vitro effects of MLC1 on GlialCAM local-
ization may be due to the presence of interacting molecules
in vivo that are not present in culture.
We also suggest that GlialCAM/MLC1 may have a role in the
process of potassium siphoning by glial cells. As a result of neuron-
al electrical activity, potassium is released in order to repolarize the
membrane potential, and this excess of potassium needs to be dis-
posed of in a process known as ‘potassium siphoning’ (49). Glial
cells surrounding neurons take up potassium by Kir4.1 channels
and then transfer it through Connexin junctions to the astrocytic
end-feet surroundingbloodvessels,where it is eliminated.Ablation
of Kir4.1 (50) or Connexins 32 and 47 (51) results in leukodystro-
phy characterized by water accumulation in myelin. Work with
Mlc12/2, GlialCAM2/2 and Clcn22/2 mice models (22,60) and
the identification of mutations in CLCN2 in human patients with
leukodystrophy (26) have suggested that the chloride channel
ClC-2 may also have a role in potassium-coupled chloride influx.
In this sense, GlialCAM changes the rectification of the ClC-2
channel (24), allowing chloride influx at depolarized voltages.
Interestingly, new studies with ClC-2 from C. elegans have also
shown that the primary role of ClC-2 is to mediate chloride
influx but not efflux (52). Unfortunately, the precise role of
MLC1 in this process is still not known. However, based on these
studies, we can speculate that it may have a regulatory role control-
ling the surface expression of GLIALCAM, which may be needed
toregulate in turn theactivityofCLC-2.Possibly, theseverityof the
phenotype caused by the depletion of Mlc1 from fish to mouse and
human could be explained based on differences in neuronal activity
between species, making Mlc1 or Glialcam more necessary to keep
ionic homeostasis in the possibly more active human CNS.
In summary, our work show that the functional relationship
between the two proteins causing MLC in vertebrates is evolu-
tionary conserved. We have also increased the diversity of ver-
tebrate animal models for this disease that can offer further
insights into the molecular interactions between these two pro-
teins. Our work also explains the similarity of phenotypes
caused by mutations in either gene. More importantly, we uncov-
ered a role for MLC1 in GlialCAM localization at astrocyte
junctions in the presence of neuronal activity, offering new
mechanistic insights into the pathophysiology of MLC.
MATERIALS ANDMETHODS
Zebrafish maintenance
AB or AB/TL strains were used in all the experiments. Adult fish
were maintained in the animal facility at the University of
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Barcelona, School of Medicine in Bellvitge Campus, under the
standard culture conditions: 288C, 14 h/10 h light/dark period
(53). All experimental procedures conformed to the European
Community Guidelines on Animal Care and Experimentation
and were approved by animal care and use committees.
The mlc1fh328 allele was obtained from the laboratory of
Dr Cecilia Moens, as a result of an ENU-based TILLING screen-
ing (62). The mutant line was generated in an islet1::GFP back-
ground, which was eliminated by out-crossing to AB wild-type
fish. Similarly, two other embryonic recessive lethal phenotypes
that were not linked to mlc1fh328 were eliminated by pair-wise
mating and out-crossing. The mlc1fh328 mutation is a T/G trans-
version inmlc1 exon 3 that generates a novelDdeI restriction site
(CTNAG), which was used for genotyping after amplifying the
corresponding fragment of genomic DNA by PCR. The follow-
ing oligonucleotides were used: TAAATGTGTCTATCTG
TATCTGACCGTCAG (underlined is a mutation introduced
to eliminate an endogenous DdeI restriction site, 16 nucleotides
upstream from the DdeI restriction site generated by the muta-
tion) and TACTCTGCAAGCCAAAAGCA. Genomic DNA
was obtained from tail clipping and extraction by Nucleo Spin
Tissue kit (Macherey-Nagel).
Mlc1 knockout mice
Mlc12/2 mice were generated by ICS (Institut Clinique de la
Souris, Strasbourg, France) as described previously (22).
Human samples
The MLC patient sample analysed here was already reported
(13). Briefly, she carried a homozygous mutation in the MLC1
gene, resulting in an amino acid change (p.S69L) that leads to
the reduced stability of the MLC1 protein and its practical
absence.
Molecular biology
Plasmids used were constructed using standard molecular
biology techniques employing recombinant PCR and the Multi-
site Gateway system (Invitrogen). The integrity of all cloned
constructs was confirmed by DNA sequencing. For localization
studies in HeLa cells, proteins were C-terminally fused to the
FLAG epitope or HA-tagged and cloned into the pcDNA3
vector (Invitrogen).
RT-PCR
Adult zebrafish were euthanized using an overdose of tricaine
(MS222, Sigma), and tissues were quickly dissected and flash-
frozen in liquid nitrogen. Total RNA was isolated with
TRIZOL (Life Technologies) and retro-transcribed (RT-PCR)
using random hexamers with SuperScript III system (Life Tech-
nologies). The following oligonucleotides pairs were used for
qPCR: GCACGTTCAGTGGACAACTG and CACAATCATT
GGGCCTTCAG (mlc1), CCCACCCACCAAGACTAAGC
and CATCCTCAGTCGTGCTCATCTG (glialcama), and as
internal controls (54): CTGGAGGCCAGCTCAAACAT and
ATCAAGAAGAGTAGTACCGCTACCATTAC (ef1a), TCT
GGAGGACTGTAAGAGGTATGC and AGACGCACAATC
TTGAGAGCAG (rpl13a). qPCR was performed with SYBR
Select reagent (Life Technologies) in a StepOne apparatus
(Life Technologies). The expression levels were calculated
using the comparative Ct method normalized to the internal
control genes. The final results were expressed as the relative
RNA levels as indicated in the corresponding figures, taking
into account the efficiency of each primer pair with the Pfaffl
method (55).
Generation of custom antibodies against zebrafish proteins
Immune sera against synthetic peptides from zebrafish mlc1
(QREEASAQEVFSYAQMST, corresponding to amino acids
2–19, in green in Supplementary Material, Fig. S1B) and zebra-
fish glialcama (EDPPTDGENTMHHHSLPR, corresponding to
amino acids 405–422, in green in Supplementary Material,
Fig. S2B) were raised in rabbits using the services provided by
Eurogentec. The peptide was coupled to keyhole limpet haemo-
cyanin via a cysteine residue that has been added to the
N-terminal end of the peptide for mlc1 and to the C-terminal
of the peptide for glialcama. After four boosts of immunization,
the antisera were affinity purified using the peptide covalently
coupled to Sulpholink (Pierce). The polyclonal antibodies
were tested by immunoblotting and immunofluorescence on
HeLa cells expressing mlc1 or glialcama and on zebrafish
brain tissue.
Cell culture and immunofluorescence microscopy
HeLa cells were grown on DMEM containing 10% (v/v) fetal
bovine serum (Sigma) and 1% penicillin/streptomycin at 378C
in a humidity controlled incubator with 10% CO2. Cells were
cultured and transfected with the Transfectin reagent
(BioRad). Twenty-four hours after transfection, the cells were
splitted and transferred into glass-covered petri dishes in
which experiments were performed after further 24–48 h. To
detect expressed proteins, immunofluorescence staining of
cells was performed. They were fixed with phosphate-buffered
saline (PBS) containing 3% paraformaldehyde for 15 min,
blocked and permeabilized with 10% FBS and 0.1% Triton
X-100 in PBS for 2 h at room temperature (RT). Primary anti-
bodies were diluted in the same solution and incubated overnight
at 48C. Cells were washed and incubated for 2 h at RT with sec-
ondary antibodies. Cover slips were mounted in Vectashield
medium (Vector Laboratories) with 1.5 mg/ml DAPI (Sigma)
and visualized using an Olympus DSU spinning disk confocal.
Images were analysed using ImageJ. Pairs of cells were
analysed manually and quantified as being in junctions or
not being in junctions (around the plasma membrane or intra-
cellular). Intensity profile analysis was used to discern the
localization.
Histological staining methods
For immunofluorescence in zebrafish, individuals were deeply
anaesthetized in 0.1% tricaine (MS222, Sigma) in fresh water,
and then transcardiacally perfused with 4% paraformaldehyde.
Fish heads were post-fixed for 24 h at RT. Then brains and
eyes were dissected out, cryoprotected and frozen with liquid
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nitrogen-cooled methylbutane. Transverse sections (12 mm
thick) were cut on a cryostat and mounted onto gelatinized slides.
Sections were rinsed in PBS and pre-incubated with normal
goat serum (Sigma, 1:100) for 1 h. Next, they were incubated
with a primary antibody or a cocktail of primary antibodies over-
night at room temperature. Antibody dilutions used were: rabbit
anti-zebrafish mlc1, 1:100; rabbit anti-zebrafish glialcama,
1:100; mouse anti-gfap (ZIRC), 1:500; rat anti-GFP (Nacalai
Tesque), 1:1000. After PBS washes, sections were incubated
with secondary fluorescent antibodies (Alexa Fluor 488 or
568, 1:500, Invitrogen) for 1 h. After additional PBS washes, sec-
tions were mounted using the glycerol-based mounting medium.
For haematoxylin–eosin staining, we used paraffin sections
from tissue fixed in Bouin’s fixative. Sections were de-waxed
and stained using Meyer’s haematoxylin followed by eosin.
Sections were dehydrated and mounted for imaging.
Zebrafish sections were observed and photographed either
under a laser scanning confocal microscope (Nikon A1R) or a
bright-field microscope (Nikon E100). Images were adjusted
for brightness and contrast with Adobe Photoshop or Corel
Photopaint, and they were assembled with Adobe Illustrator.
Human samples were processed and analysed as described
previously (13).
Electron microscopy
For electron immunogold experiments, small samples of brain
mice tissue were obtained and fixed in 4% paraformaldehyde
and 0.1% glutaraldehyde in 0.12 M phosphate buffer, and pro-
cessed. They were cryoprotected gradually in sucrose and cryo-
fixed by immersion in liquid propane. Freeze substitution was
performed at2908C during 3 days in an Automatic Freeze Sub-
stitution System (AFS, Leica); methanol containing 0.5% urany-
lacetate was used as a substitution medium. Infiltration was
carried out in Lowicryl HM20 at 2508C and then polymerized
with UV light. Ultrathin sections were collected, and when
needed, processed for post embedding immunostaining. For
immunostaining, grids were incubated with rabbit anti-Mlc1
(1:10) or mouse anti-GlialCAM (1:10) antisera. The binding of
the primary antibody was visualized by incubating with a sec-
ondary antibody conjugated to 18 nm gold particles (British
BioCell, International). Ependymal cells were recognized by
their epithelial location, presence of microvilli and cilia, and
high density of organelles in the cytoplasm. Astrocytic processes
showed a cytoplasm light appearance with the presence of some
fibrils and a very few number of organelles (56).
For electron microscopy of zebrafish myelin sheaths, zebra-
fish were anaesthetized and transcardially perfused using 4%
paraformaldehyde and 0.1% glutaraldehyde in 0.1 M cacodylate
buffer with 0.5% calcium chloride. Small pieces of tissue were
post-fixed in the same fixative (2 h) and then in 1% osmium
tetroxide—with 1.5% potassic ferrocyanide (2 h). Tissue was
then dehydrated and included in an epoxy resin. Semithin and
thin sections were obtained using an ultramicrotome, mounted
and imaged in an electron transmission microscope.
Astrocyte cultures from wild-type and Mlc12/2 mice
Mouse astrocyte cultures were performed as previously
described from P0 to P2 mouse pups of the corresponding
genotype (16). Calcein stainings were performed by treating
the astrocytes with Calcein-AM 2 mM (Life Technologies) for
10 min and then with physiological solution (122 mM NaCl,
3.3 mM KCl, 0,4 mM MgSO2, 1.3 mM CaCl2, 1.2 mM KH2PO4,
25 mM Hepes, 10 mM glucose, pH 7.2, 300 mOsm/kg). In some
experiments, astrocytes were treated for 6 h with physiological
solution or high potassium medium (60 mM NaCl, 60 mM KCl,
0.4 mM MgSO2, 1.3 mM CaCl2, 1.2 mM KH2PO4, 25 mM
Hepes, 10 mM glucose, pH 7.2, 300 mOsm/kg), to mimic neur-
onal activity. Then, they were fixed in 4% PFA and processed
for immunofluorescence as described above.
Mouse magnetic resonance imaging
Mouse MRI experiments were conducted on a 7.0T BioSpec 70/
30 horizontal animal scanner (Bruker BioSpin), equipped with a
12 cm inner diameter actively shielded gradient system
(400 mT/m) in at least seven animals of the same age. Receiver
coil was a phased array surface coil for mouse brain. Animals
were placed in a supine position in a Plexiglas holder with a
nose cone for administering anaesthetic gases (isofluorane in a
mixture of 30% O2 and 70% CO2), fixed using a tooth bar, ear
bars and adhesive tape. Tripilot scans were used for accurate
positioning of the animal’s head in the isocentre of the magnet.
High-resolution T2-weighted images were acquired by using
TurboRARE (rapid acquisition with rapid enhancement) se-
quence applying repetition time of 2969 ms, echo time of
36 ms, RARE factor ¼ 8, 10 averages, slice thickness ¼
0.3 mm, number of slices ¼ 25 for horizontal view, 25 coronal
slices, field of view ¼ 25 × 25 mm, matrix size ¼ 240 × 240
pixels, resulting in a spatial resolution of 0.104 × 0.104 mm in
0.3 mm slice thickness.
T2 relaxometry maps were acquired with multislice-
multiecho (MSME) sequence by applying 16 different TEs,
from 11 to 176 ms, TR ¼ 4764 ms, slice thickness ¼ 0.5 mm,
number of coronal slices ¼ 18, FOV ¼ 20 × 20 mm and
matrix size ¼ 256 × 256 pixels, resulting in a spatial resolution
of 0.078 × 0.078 mm in 0.5.00 mm slice thickness.
Zebrafish magnetic resonance imaging
Magnetic resonance microimaging (mMRI) of zebrafish was
performed on a vertical wide-bore 9.4T Bruker Avance
400WB spectrometer, with a 1000 mT/m actively shielded
imaging gradient insert (Bruker Biospin GmbH). A birdcage
RF coil with an inner diameter 1 cm was used for excitation
and detection. The system was interfaced to a Linux PC
running Topspin 2.0 and Paravision 5.0 software (Bruker
Biospin GmbH). For mMRI, adult zebrafish were euthanized
and fixed in 4% buffered paraformaldehyde (Zinc Formal-Fixx,
ThermoShandon) for 3 days and subsequently embedded in
Fomblin. Before each mMRI measurement, the magnetic field
homogeneity was optimized by shimming. Each session of mea-
surements began with a multislice orthogonal gradient-echo se-
quence for position determination and selection of the desired
region for subsequent experiments. High-resolution T2-
-weighted imaging was acquired by using TurboRARE (rapid
acquisition with rapid enhancement) sequences with echo time
(TE) ¼ 10.5 ms; repetition time (TR) ¼ 5000 ms; RARE
factor ¼ 4; slice thickness 0.2 mm; number of slices 15; field
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of view 12 × 12 mm; image matrix of 256 × 256 pixels, result-
ing in an in-plane resolution of 47 mm.
T2 relaxation time measurement in zebrafish brain was per-
formed with MSME sequence by applying eight different TEs
(8.5, 17.0, 25.5, 34.0, 42.5, 51.0, 59.5 and 68.0 ms); TR ¼
1.5 s; slice thickness 0.5 mm; number of slices 6, FOV 12 ×
12 mm2 and matrix size 256 × 256 pixels, resulting in an
in-plane resolution of 47 mm. For calculation of T2 relaxation
time, regions of interest (ROIs) were drawn at various locations
within the zebrafish brain. Another ROI in the muscle was used
as an internal control. Means and standard deviation forT2 relax-
ation times for each ROI were calculated.
Two-electrode voltage clamp, western and surface
expression in Xenopus oocytes
Xenopus oocytes were injected and maintained as described
(57). For rat ClC-2, 10 ng cRNA were injected. When
co-expressing, 5 ng cRNA of glialcama or glialcambwere coin-
jected with rat ClC-2. Oocytes were perfused with ND96 (in
mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2 and 5 HEPES/TRIS
(pH 7.4). To estimate the specific ClC-2-mediated chloride cur-
rents, iodide (80 mM NaI replacing the NaCl), which blocks
ClC-2-mediated outward currents (58), was applied in every
experiment. Oocytes that did not exhibit a significant block
were discarded. Currents were measured using a TEC-05X
voltage amplifier and the CellWorks program (npi).
Western blot experiments and surface expression in oocytes
were performed similarly as previously described (6).
Zebrafish electroretinogram recordings
ERGs were performed at 1-month and 2-month-old young adults
(at least five animals). The young adults were anaesthetized by
fish system water containing 0.75 mM 3-aminobenzoic acid
methyl ester (MESAB, Sigma-Aldrich) and 4.6 mM NaHCO3
before recording. All the experiments were performed at room
temperature (208C).
Fish were dark adapted for at least 30 min and then were placed
on the filter paper in the middle of a plastic recording chamber
which was filled by 1% agarose. The reference electrode was
inserted into the agarose. After the fish was moisturized by a
drop of Ringer´s solution (111 mM NaCl, 2.5 mM KCl, 1 mM
CaCl2, 1.6 mM MgCl2, 10 mm EDTA, 10 mM glucose and 3 mM
HEPES buffer, adjusted to pH 7.7–7.8 with NaOH), the eye
was removed by a loop made of tungsten wire. The loop was
placed behind the eye and was pressed down to cut the optic
nerve. Meanwhile forceps were used to pull the body and
discard it. The isolated eye was then positioned to face the light
source (ZEISS XBO 75 W). The recording electrode, filled with
Ringer’s solution, was placed against the centre of the cornea.
All these pre-recording steps were done under dim red illumin-
ation. Stimulation light intensity was 6000 lux and attenuated
by neutral density filters. Stimulus duration was 100 ms and deliv-
ered 50 ms after the recording began. Electronic signals were
amplified 1000 times by a pre-amplifier (P55 A.C. Preamplifier,
Astro-Med. Inc, Grass Technology) with a band pass between
0.1 and 100 Hz, digitized by DAQ Board NI PCI-6035E (National
Instruments) via NI BNC-2090 accessories and displayed via
self-developed NI Labview program (59). All the figures were
prepared by Origin (Microcal Software).
Mouse electroretinogram recording
The mice were dark-adapted overnight before ERG recording.
Under dim red light (l . 600 nm), the mice were anaesthetized
with an i.p. injection of a solution of ketamine (70 mg/kg, Keto-
larw, Parke-Davies, S.L.) and xylazine (10 mg/kg, Rompu´nw)
and kept on a heating pad to maintain normal body temperature
at 378C. A topical drop of 1% tropicamide (Colicursı´ Tropica-
mida 1%w; Alcon-Cusı´, S.A.) were applied to the eyes of the ex-
perimental animals before ERG testing. Electrical responses
were obtained with Burian-Allen electrodes (Hansen Labs) posi-
tioned on the cornea. A drop of methylcellulose (Methocel 2%w;
Novartis Laboratories CIBA Vision) was positioned on the
cornea to improve electrical conductivity. The reference elec-
trode was placed in the mouth, and the ground electrode at the
base of the tail. After positioning the electrodes, the mice were
placed in a Ganzfeld stimulator. Stimulation flashes were pro-
vided by a Ganzfeld dome light source, which ensured a
uniform illumination of the retina and provided a wide range
of light intensities. Electrical signals generated in the retina
were amplified (×1000) and band filtered between 0.3 and
1000 Hz, using a Grass amplifier (CP511 AC amplifier, Grass
Instruments). Electrical signals were digitized at 20 kHz, using
a Power Lab data acquisition board (AD Instruments) and dis-
played on a PC computer monitor. The ERG responses were eli-
cited by stimulation of the retina with light intensities ranging
between 1024 and 102 cd/s/m22. A series of ERG responses
were averaged (≈20 ERG traces) for each light intensity, after
adjusting the time interval between flashes to ensure complete
recovery of the response. Standard ERG waves were recorded
according to the method recommended by the International
Society for Clinical Electrophysiology of Vision (ISCEV).
Electrophysiological measurements on mouse astrocytes
Electrophysiological measurements were performed with the
whole-cell configuration of the patch-clamp technique as previ-
ously described (60). Briefly, pipette had a resistance of 2–4 MV
when filled with the intracellular solution. Membrane currents
were amplified (amplifier List EPC-7) filtered at 2 kHz
(23 dB) and acquired at a sample rate of 5 kHz on a microcom-
puter for off-line analyses (pClamp 6, Axon Instruments and
Origin 6.0, MicroCal). The access resistance (below 10 MV)
was corrected for 60–80%. Current densities were calculated
by dividing the current values measured at each membrane po-
tential by the cell capacitance estimated from the capacitive tran-
sients of the recorded cells corrected by means of the analogical
circuit of the patch-clamp amplifier. For the isolation of the Cl2
conductance, the external perfusing saline, called isotonic (Iso
CsCl), was (mM): 122 CsCl, 2 MgCl2, 2 CaCl2, 10 TES, 5
glucose, pH 7.4 with CsOH and osmolality 320 mOsm with
mannitol. The intracellular (pipette) solution was composed of
(mM): 126 CsCl, 2 MgCl2, 1 EGTA, 10 TES, pH 7.2 and osmo-
lality300 mOsm with mannitol. Hypotonic extracellular solu-
tion (Hypo CsCl) 260 mOsm was obtained by omitting
mannitol. Osmolality was measured with a vapour–pressure
osmometer (Wescor 5500, Delcon). All salts and various
5084 Human Molecular Genetics, 2014, Vol. 23, No. 19
molecules were from Sigma. The DCPIB was prepared in DMSO
at a concentration 1000-fold higher than that used in the
perfusing saline.
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